Recruiting NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Enoxaparin, warfarrin, or apixaban.
- Who it may be relevant to
- Registry conditions: Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma
Overview
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Interventions
- Drug Enoxaparin, warfarrin, or apixaban
Enoxaparin, warfarrin, or apixaban
Primary outcome measures
- Portal vein thrombosis [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B
Exclusion criteria
- Platelets<10000, Createnine >1.9, Budd ciarri, Uncontrolled active bleeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Mansoura University Hospitals — Al Mansurah
Identifiers
NCT: NCT07132515 · MS.23.07.2479